This article is more than 5 years old. Information may no longer be current.
Last patient dosed in Aldeyra allergic conjunctivitis treatment trial
The last patient in the ALLEVIATE phase 3 trial of topical ocular reproxalap for allergic conjunctivitis has been dosed, Aldeyra Therapeutics announced.
The multicenter, double-masked, parallel-group, vehicle-controlled phase 3 clinical trial enrolled more than 300 patients who randomly received topical ocular 0.25% reproxalap, 0.5% reproxalap or vehicle. Patient-reported ocular itching is the primary outcome measure.
“Affecting approximately 20% of the population worldwide, allergic conjunctivitis is a common disease that can cause persistently disturbing symptoms and is often associated with dry eye disease,” Todd C. Brady, MD, PhD, Aldeyra president and CEO, said in a press release. “Reproxalap’s novel mechanism has the potential to be uniquely effective in allergic conjunctivitis and may offer increased durability of activity relative to standard of care.”
Results from the clinical trial are expected in early 2019.